Sodium nitrite - Hope Pharmaceuticals

Drug Profile

Sodium nitrite - Hope Pharmaceuticals

Latest Information Update: 03 Oct 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hope Pharmaceuticals
  • Developer Hope Pharmaceuticals; Johns Hopkins University
  • Class Antidotes; Antihypertensives; Nitrites; Small molecules; Sodium compounds; Vasodilators
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myocardial infarction; Subarachnoid haemorrhage

Most Recent Events

  • 09 May 2017 Hope Pharmaceuticals terminates a phase II trial in Subarachnoid haemorrhage in USA (IV) (NCT02176837)
  • 22 Aug 2016 Sodium nitrite is still in phase II trials for Subarachnoid haemorrhage and Myocardial infarction in USA (IV)
  • 01 Jun 2016 Hope Pharmaceuticals and Johns Hopkins University completes a phase II trials in Subarachnoid haemorrhage and Myocardial infarction in USA (IV) (NCT00924118)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top